Abstract：
To report preliminary findings of hypofractionated superficial radiotherapy for treatment of cutaneous mast cell tumors (MCTs) and report the acute and late toxicity associated with its use.
3 dogs and 1 cat.
In this retrospective study, medical records from January 2021 through July 2022 were searched for animals that received superficial radiation therapy for MCTs of the head.
4 patients with 5 MCTs were included. Three of the masses were periocular and required protection of the globe with a tungsten eye shield. One patient did not complete the intended protocol due to diffuse metastatic spread noted after the second fraction. Of the 3 patients that completed their protocol, 100% had a complete response. Two canine patients were treated adjunctively with toceranib. Two of the 4 patients experienced grade 1 acute veterinary radiation therapy oncology group (VRTOG) toxicity, and the 3 patients that completed their protocol experienced grade 1 late VRTOG toxicity. No radiation effects were documented to the cornea or lens in any patient.
Superficial radiation therapy was effective in our limited study population, and patients experienced minimal side effects for treatment of cutaneous MCTs.
3 dogs and 1 cat.
In this retrospective study, medical records from January 2021 through July 2022 were searched for animals that received superficial radiation therapy for MCTs of the head.
4 patients with 5 MCTs were included. Three of the masses were periocular and required protection of the globe with a tungsten eye shield. One patient did not complete the intended protocol due to diffuse metastatic spread noted after the second fraction. Of the 3 patients that completed their protocol, 100% had a complete response. Two canine patients were treated adjunctively with toceranib. Two of the 4 patients experienced grade 1 acute veterinary radiation therapy oncology group (VRTOG) toxicity, and the 3 patients that completed their protocol experienced grade 1 late VRTOG toxicity. No radiation effects were documented to the cornea or lens in any patient.
Superficial radiation therapy was effective in our limited study population, and patients experienced minimal side effects for treatment of cutaneous MCTs.
摘要：
目的：报道大分割浅表放疗治疗皮肤肥大细胞瘤（MCTs）的初步发现，并报道其急性和晚期毒性。
方法：3只狗和1只猫。
方法：在这项回顾性研究中，我们在2021年1月至2022年7月的医疗记录中搜索了头部MCT接受浅层放射治疗的动物.
结果：纳入4例5例MCT。其中三个肿块是眼周的，需要用钨眼罩保护眼球。由于在第二部分之后注意到的弥漫性转移扩散,一名患者没有完成预期的方案。在完成协议的3名患者中，100%有完整的反应。两名犬患者接受了toceranib的辅助治疗。4例患者中有2例经历了1级急性兽医放射治疗肿瘤组（VRTOG）毒性，完成方案的3例患者出现1级晚期VRTOG毒性。没有记录到任何患者的角膜或晶状体的辐射效应。
结论：在我们有限的研究人群中，浅层放射治疗是有效的，患者在治疗皮肤MCT时副作用最小。
方法：3只狗和1只猫。
方法：在这项回顾性研究中，我们在2021年1月至2022年7月的医疗记录中搜索了头部MCT接受浅层放射治疗的动物.
结果：纳入4例5例MCT。其中三个肿块是眼周的，需要用钨眼罩保护眼球。由于在第二部分之后注意到的弥漫性转移扩散,一名患者没有完成预期的方案。在完成协议的3名患者中，100%有完整的反应。两名犬患者接受了toceranib的辅助治疗。4例患者中有2例经历了1级急性兽医放射治疗肿瘤组（VRTOG）毒性，完成方案的3例患者出现1级晚期VRTOG毒性。没有记录到任何患者的角膜或晶状体的辐射效应。
结论：在我们有限的研究人群中，浅层放射治疗是有效的，患者在治疗皮肤MCT时副作用最小。
